Aqueous penetration of moxifloxacin 0.5% ophthalmic solution and besifloxacin 0.6% ophthalmic suspension in cataract surgery patients

Journal of Cataract and Refractive Surgery

Volumn 36, Issue 9, 2010, Pages 1499-1502

  Yoshida, Junko ^a   Kim, Alisa ^a   Pratzer, Kimberly A ^a   Stark, Walter J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS ACTING ON THE EYE; BESIFLOXACIN; MOXIFLOXACIN; UNCLASSIFIED DRUG; 7-(3-AMINOHEXAHYDRO-1H-AZEPIN-1-YL)-8-CHLORO-1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-4-OXO-3-QUINOLINECARBOXYLIC ACID; ANTIINFECTIVE AGENT; AZEPINE DERIVATIVE; EYE DROPS; HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; AGED; AQUEOUS HUMOR; ARTICLE; CATARACT EXTRACTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG PENETRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PARACENTESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURGICAL TECHNIQUE; COMPARATIVE STUDY; CORNEA; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; AQUEOUS HUMOR; AZA COMPOUNDS; AZEPINES; CATARACT EXTRACTION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORNEA; DOUBLE-BLIND METHOD; FLUOROQUINOLONES; HUMANS; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; QUINOLINES;

EID: 77955565566     PISSN: 08863350     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcrs.2010.04.030     Document Type: Article

References (20)

1. S. Herretes, W.J. Stark, A. Pirouzmanesh, J.M.G. Reyes, P.J. McDonnell, and A. Behrens Inflow of ocular surface fluid into the anterior chamber after phacoemulsification through sutureless corneal cataract wounds Am J Ophthalmol 140 2005 737 740
2. M. Taban, M.A. Sarayba, T.S. Ignacio, A. Behrens, and P.J. McDonnell Ingress of India ink into the anterior chamber through sutureless clear corneal cataract wounds Arch Ophthalmol 123 2005 643 648
3. M. Taban, A. Behrens, R.L. Newcomb, M.Y. Nobe, G. Saedi, P.M. Sweet, and P.J. McDonnell Acute endophthalmitis following cataract surgery; a systematic review of the literature Arch Ophthalmol 123 2005 613 620
4. ESCRS Endophthalmitis Study Group Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors J Cataract Refract Surg 33 2007 978 988
5. P. Barry, S. Gardner, D. Seal, G. Gettinby, F. Lees, M. Peterson, and C. Revie Clinical observations associated with proven and unproven cases in the ESCRS study of prophylaxis of postoperative endophthalmitis after cataract surgery; the ESCRS Endophthalmitis Study Group J Cataract Refract Surg 35 2009 1523 1531
6. F.C. DeCroos, and N.A. Afshari Perioperative antibiotics and anti-inflammatory agents in cataract surgery Curr Opin Ophthalmol 19 2008 22 26
7. D.F. Chang, R. Braga-Mele, N. Mamalis, S. Masket, K.M. Miller, L.D. Nichamin, R.B. Packard, and M. Packer Prophylaxis of postoperative endophthalmitis after cataract surgery; results of the 2007 ASCRS member survey; the ASCRS Cataract Clinical Committee J Cataract Refract Surg 33 2007 1801 1805
8. D.H. Kim, W.J. Stark, T.P. O'Brien, and J.D. Dick Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients Ophthalmology 112 2005 1992 1996
9. J.P. McCulley, D. Caudle, J.D. Aronowicz, and W.E. Shine Fourth-generation fluoroquinolone penetration into the aqueous humor in humans Ophthalmology 113 2006 955 959
10. L. Ong-Tone Aqueous humor penetration of gatifloxacin and moxifloxacin eyedrops given by different methods before cataract surgery J Cataract Refract Surg 33 2007 59 62
11. D.H. Kim, W.J. Stark, and T.P. O'Brien Ocular penetration of moxifloxacin 0.5% and gatifloxacin 0.3% ophthalmic solutions into the aqueous humor following topical administration prior to routine cataract surgery Curr Med Res Opin 21 2005 93 94
12. F.S. Mah Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infections Curr Opin Ophthalmol 15 2004 316 320
13. J.S. Bertino Jr. Impact of antibiotic resistance in the management of ocular infections: the role of current and future antibiotics Clin Ophthalmol 3 2009 507 521 Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2754082/ pdf/opth-3-507.pdf Accessed May 16, 2010
14. K.M. Shea Nontherapeutic use of antimicrobial agents in animal agriculture: implications for pediatrics; American Academy of Pediatrics technical report Pediatrics 114 2004 862 910 Available at: http://pediatrics. aappublications.org/cgi/reprint/114/3/862 Accessed May 16, 2010
15. K.M. Shea Antibiotic resistance: what is the impact of agricultural uses of antibiotics on children's health? Pediatrics 112 2003 253 258 Available at: http://pediatrics.aappublications.org/cgi/reprint/112/1/S1/253 Accessed May 16, 2010
16. J.C. Major Jr., M. Engelbert, H.W. Flynn Jr., D. Miller, W.E. Smiddy, and J.L. Davis Staphylococcus aureus endophthalmitis: antibiotic susceptibilities, methicillin resistance, and clinical outcomes Am J Ophthalmol 149 2010 278 283
17. M. Yamada, J. Yoshida, S. Hatou, T. Yoshida, and Y. Minagawa Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones Br J Ophthalmol 92 2008 848 851
18. J.W. Proksch, C.P. Granvil, R. Siou-Mermet, T.L. Comstock, M.R. Paterno, and K.W. Ward Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans J Ocul Pharm Ther 25 2009 335 344
19. Marshall B, Cupp G, Foster K, McLean C, Cockrum P, Lichtenstein S, De Leon L, Heller W, Levy S, Stroman DW. "Moxifloxacin Treatment of Conjunctivitis: Microbial Effects Beyond the Eye," poster presented at 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, USA, September 2009
20. Bausch & Lomb, Inc. Dermatologic and Ophthalmic Drugs Advisory Committee Meeting Briefing Document. FDA Advisory Committee Recommends Approval of Bausch & Lomb Besifloxacin Anti-Infective Eye Drop. December 5, 2008. Available at: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4397b1-02- BauschLomb.pdf. Accessed May 16, 2010